Mt Dysfunction in NAFLD
Research type
Research Study
Full title
TO EVALUATE THE ROLE OF MITOCHONDRIAL DYSFUNCTION AS A PREDICTOR FOR DEVELOPMENT OF CIRRHOSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
IRAS ID
244792
Contact name
Saima Ajaz
Contact email
Sponsor organisation
King’s College Hospital NHS Foundation Trust
Duration of Study in the UK
0 years, 11 months, 28 days
Research summary
Non-alcoholic fatty liver disease (NAFLD) is predicted to be the most common cause of chronic liver diseases due to rise in obesity and metabolic syndrome. The spectrum of NAFLD ranges from accumulation of simple fat around the liver to Non-alcoholic steatohepatitis (NASH) and cirrhosis. Currently the mechanisms involved in the progression of benign fatty accumulation in the liver to inflammation and ultimately to scar tissue or cirrhosis are not completely understood. Mitochondrial dysfunction, inflammation and oxidative stress are suggested to play a significant role.
Mitochondria are the main energy source in hepatocytes and play a major role in extensive oxidative metabolism and normal function of the liver. Nogo-B belongs to family of proteins present in the endoplasmic reticulum and has been shown to be an indicator of liver cirrhosis. Defects in mitochondrial function or bioenergetics deficit can be utilised as a predictive marker for progression of fibrosis in NASH.
Measurement of Nogo-B levels in plasma samples of the patients by enzyme-linked immunosorbent assay will also be correlated with the functional analysis. The purpose of this proof of concept pilot study is to measure mitochondrial function as a non-invasive predictive biomarker for development of fibrosis in NASH.REC name
London - Hampstead Research Ethics Committee
REC reference
18/LO/1355
Date of REC Opinion
30 Jul 2018
REC opinion
Favourable Opinion